WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012112434) INHIBITING ABERRANT BLOOD VESSEL FORMATION USING RETARGETED ENDOPEPTIDASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/112434    International Application No.:    PCT/US2012/024845
Publication Date: 23.08.2012 International Filing Date: 13.02.2012
IPC:
C07K 14/33 (2006.01), A61K 38/16 (2006.01)
Applicants: ALLERGAN, INC. [US/US]; 2525 Dupont Drive Irvine, California 92612 (US) (For All Designated States Except US).
JACKY, Birgitte P.S. [DK/US]; (US) (For US Only).
GARAY, Patton E. [US/US]; (US) (For US Only).
MOLINA, Yanira [US/US]; (US) (For US Only).
FRANCIS, Joseph [CA/US]; (US) (For US Only).
STEWARD, Lance E. [US/US]; (US) (For US Only).
GHANSHANI, Sanjiv [US/US]; (US) (For US Only).
HUNT, Terrence J. [US/US]; (US) (For US Only).
AOKI, K. Roger [US/US]; (US) (For US Only).
FERNANDEZ-SALAS, Ester [US/US]; (US) (For US Only)
Inventors: JACKY, Birgitte P.S.; (US).
GARAY, Patton E.; (US).
MOLINA, Yanira; (US).
FRANCIS, Joseph; (US).
STEWARD, Lance E.; (US).
GHANSHANI, Sanjiv; (US).
HUNT, Terrence J.; (US).
AOKI, K. Roger; (US).
FERNANDEZ-SALAS, Ester; (US)
Agent: ABEL, Kenton B.; Allergan, Inc. 2525 Dupont Drive Irvine, California 92612 (US)
Priority Data:
61/442,769 14.02.2011 US
61/445,030 21.02.2011 US
Title (EN) INHIBITING ABERRANT BLOOD VESSEL FORMATION USING RETARGETED ENDOPEPTIDASES
(FR) PROCÉDÉ PERMETTANT D'INHIBER LA FORMATION DE VAISSEAUX SANGUINS ABERRANTS AU MOYEN D'ENDOPEPTIDASES RECIBLÉES
Abstract: front page image
(EN)The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions.
(FR)La présente invention concerne des protéines à modulation d'exocytoses vésiculaires ciblées (TVEMP), des compositions comportant de telles protéines TVEMP et des méthodes de traitement d'une maladie ou d'un trouble associé à la formation de nouveaux vaisseaux sanguins aberrants chez un mammifère au moyen de telles compositions de protéines TVEMP.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)